Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer Lele ChangXuemei ZhangQingwei Li Research Open access 17 February 2024 Pages: 161 - 170
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study Miaomiao GouYong ZhangGuanghai Dai Research Open access 12 February 2024 Pages: 171 - 178
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma Kathryn E. BeckermannAmita PatnaikBrian I. Rini Research 19 February 2024 Pages: 179 - 184
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma Xinxiu LiHongmeng SuHong Fan Research 19 February 2024 Pages: 185 - 195
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab? Yuanyuan ZhaoTing MeiYouling Gong Research Open access 22 February 2024 Pages: 196 - 206
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages Petra HenningAnna WesterlundUlf H. Lerner Research Open access 01 March 2024 Pages: 207 - 220
A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer Andrew H. KoAndrew L. CovelerShih-Yao Lin Research 05 March 2024 Pages: 221 - 228
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status Aaron ShaykevichDanbee ChaeRadhashree Maitra Research Open access 06 March 2024 Pages: 229 - 239